Tags

Type your tag names separated by a space and hit enter

Comparative profile of tizanidine in the management of spasticity.
Neurology. 1994 Nov; 44(11 Suppl 9):S53-9.Neur

Abstract

The therapeutic profile of a new antispastic drug cannot be defined solely on the basis of placebo-controlled studies. Its potential advantages must be evaluated in comparison with existing drugs. This review compares the efficacy and tolerability of tizanidine, a newer muscle relaxant, with that of baclofen and diazepam, the most widely used antispastic agents, for a variety of diagnoses and target symptoms associated with spasticity. More than 20 double-blind, comparative studies were conducted between 1977 and 1987. These included a total of 777 patients suffering from spasticity of various causes. The collected clinical data have been integrated into a combined analysis. Tizanidine emerges from this comparison as a valuable drug in the treatment of spasticity related to cerebral and spinal disorders.

Authors+Show Affiliations

CNS Department, Clinical Research & Development, Sandoz Pharma Ltd, Basel, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis

Language

eng

PubMed ID

7970011

Citation

Lataste, X, et al. "Comparative Profile of Tizanidine in the Management of Spasticity." Neurology, vol. 44, no. 11 Suppl 9, 1994, pp. S53-9.
Lataste X, Emre M, Davis C, et al. Comparative profile of tizanidine in the management of spasticity. Neurology. 1994;44(11 Suppl 9):S53-9.
Lataste, X., Emre, M., Davis, C., & Groves, L. (1994). Comparative profile of tizanidine in the management of spasticity. Neurology, 44(11 Suppl 9), S53-9.
Lataste X, et al. Comparative Profile of Tizanidine in the Management of Spasticity. Neurology. 1994;44(11 Suppl 9):S53-9. PubMed PMID: 7970011.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative profile of tizanidine in the management of spasticity. AU - Lataste,X, AU - Emre,M, AU - Davis,C, AU - Groves,L, PY - 1994/11/1/pubmed PY - 1994/11/1/medline PY - 1994/11/1/entrez SP - S53 EP - 9 JF - Neurology JO - Neurology VL - 44 IS - 11 Suppl 9 N2 - The therapeutic profile of a new antispastic drug cannot be defined solely on the basis of placebo-controlled studies. Its potential advantages must be evaluated in comparison with existing drugs. This review compares the efficacy and tolerability of tizanidine, a newer muscle relaxant, with that of baclofen and diazepam, the most widely used antispastic agents, for a variety of diagnoses and target symptoms associated with spasticity. More than 20 double-blind, comparative studies were conducted between 1977 and 1987. These included a total of 777 patients suffering from spasticity of various causes. The collected clinical data have been integrated into a combined analysis. Tizanidine emerges from this comparison as a valuable drug in the treatment of spasticity related to cerebral and spinal disorders. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/7970011/Comparative_profile_of_tizanidine_in_the_management_of_spasticity_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=7970011.ui DB - PRIME DP - Unbound Medicine ER -